1. Summary Information
|
|
|
Country |
|
|
Company Name |
AGIO
PHARMACEUTICALES LIMITED |
Principal Name 1 |
Mr. Madhusudan Ruia |
|
Status |
Satisfactory |
Principal Name 2 |
Mr. Gautam sushil Ruia |
|
|
|
Registration # |
11-065031 |
|
Street Address |
A-38, Nandjyot
Industrial Estate, Kurla Andheri Road, Safed Pool, Mumbai – 400072, Maharashtra |
||
|
Established Date |
24.03.1992 |
SIC Code |
-- |
|
Telephone# |
91-22-28518204 |
Business Style 1 |
Manufacturer |
|
Fax # |
91-22-28518204 |
Business Style 2 |
- |
|
Homepage |
- |
Product Name 1 |
Pharmaceutical Products |
|
# of employees |
Not Available |
Product Name 2 |
Chemical Products |
|
Paid up capital |
Rs.50,082,950
/- |
Product Name 3 |
- |
|
Shareholders |
Foreign holdings -
10.32% Bodies corporate – 22.46% Directors or
relatives of Director – 67.22% |
Banking |
Union Bank of
India |
|
Public Limited Corp. |
NO |
Business Period |
20 Year |
|
IPO |
NO |
International Ins. |
- |
|
Public |
NO |
Rating |
Ba (46) |
|
Related
Company |
|||
|
Relation
|
India |
Company
Name |
CEO |
|
-- |
-- |
-- |
-- |
|
Note |
- |
||
2. Summary
Financial Statement
|
Balance Sheet as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Assets |
Liabilities |
||
|
Current Assets |
829,164,000 |
Current Liabilities |
340,503,000 |
|
Inventories |
290,559,000 |
Long-term Liabilities |
756,066,000 |
|
Fixed Assets |
363,567,000 |
Other Liabilities |
18,020,000 |
|
Deferred Assets |
0,000 |
Total Liabilities |
1,114,589,000 |
|
Invest& other Assets |
3,913,000 |
Retained Earnings |
3,22,531,000 |
|
|
|
Net Worth |
3,72,614,000 |
|
Total Assets |
1,487,203,000 |
Total Liab. & Equity |
1,487,203,000 |
|
Total Assets (Previous Year) |
1,215,130,000 |
|
|
|
P/L Statement as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Sales |
1,377,975,000 |
Net Profit |
14,054,000 |
|
Sales(Previous yr) |
981,413,000 |
Net Profit(Prev.yr) |
12,773,000 |
MIRA
INFORM REPORT
|
Report Date : |
05.04.2012 |
IDENTIFICATION DETAILS
|
Name : |
AGIO PHARMACEUTICALES LIMITED |
|
|
|
|
Registered
Office : |
A-38, Nandjyot Industrial Estate, Kurla Andheri Road, Safed Pool, Mumbai – 400072, Maharashtra |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2011 |
|
|
|
|
Date of
Incorporation : |
24.03.1992 |
|
|
|
|
Com. Reg. No.: |
11-065031 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.50.083 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U2423MH1992PLC065031 |
|
|
|
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
MUMM23543C MUMM20995C |
|
|
|
|
PAN No.: [Permanent Account No.] |
AABCA8426A |
|
|
|
|
Legal Form : |
A Closely Held Public Limited
Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer of Prescription Drugs |
|
|
|
|
No. of Employees
: |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (46) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 1500000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established company having satisfactory track. Trade
relations are reported as fair. Business is active. Payments are reported to
be usually correct and as per commitment. The company can be considered for normal for business dealings at
usual trade terms and condition. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
LOCATIONS
|
Registered Office / Marketing and Administrative office : |
A-38, Nandjyot Industrial Estate, Kurla Andheri Road, Safed Pool, Mumbai – 400072, Maharashtra, India |
|
Tel. No.: |
91-22-28518204 |
|
Fax No.: |
91-22-28518204 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
|
|
|
Corporate Office : |
Mittal Tower, C- Wing 113, 11th Floor, Nariman Point,
Mumbai – 400021, Maharashtra, India |
|
Tel. No.: |
91-22-22826885 / 42320000 |
|
Fax No.: |
91-22-22826885 |
|
E-Mail : |
|
|
|
|
|
Factory : |
T-81, T-82, MIDC, Bhosari, Pune – 411026, Maharashtra, India |
|
Tel. No.: |
91-20-40730000 / 30683366 / 30683367 |
|
Fax No.: |
91-20-40730002 |
|
E-Mail : |
|
|
|
|
|
|
|
|
Overseas Branch Office : |
Located At ·
Moscow, Russia ·
Tashkent, Uzbekistan ·
Kiev, Ukraine |
DIRECTOR
As on 30.09.2011
|
Name : |
Mr. Madhusudan Ruia |
|
Designation : |
Managing Director |
|
Address : |
10th Floor, Shivam Apartment, Near Babulnath Temple, Grand
Road (West), Mumbai – 400007, Maharashtra, India |
|
Date of Birth/Age : |
19.08.1957 |
|
Date of Appointment : |
24.01.1992 |
|
DIN No.: |
00018971 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Date
of cessation |
Company
Status |
Defaulting
status |
|
1 |
U24239MH1992PLC065031 |
AGIO
PHARMACEUTICALS LIMITED |
Managing
director |
24-01-92 |
24-01-92 |
- |
Active |
NO |
|
2 |
U24230MH1998PTC117547 |
SHREE
FLEX PRINT PRIVATE LIMITED |
Director |
01-11-00 |
01-11-00 |
- |
Active |
NO |
|
3 |
U65920MH1985PTC037699 |
IRIS
PROPERTIES PRIVATE LIMITED |
Director |
11-06-02 |
11-06-02 |
- |
Amalgamated |
NO |
|
4 |
U24230MH1996PTC096954 |
REVIVE
PHARMACEUTICALS PRIVATE LIMITED |
Director |
06-02-04 |
06-02-04 |
- |
Active |
NO |
|
5 |
U24231MH1994PTC079977 |
GENOME
PHARMACEUTICALS AND CHEMICALS PRIVATE LIMITED |
Director |
06-02-04 |
06-02-04 |
- |
Active |
NO |
|
6 |
U24230MH2004PLC148151 |
VIDA
MEDICAREZ LIMITED |
Director |
20-08-04 |
20-08-04 |
- |
Active |
NO |
|
7 |
U52520MH2001PTC130447 |
ONE-STOP
SHOP INDIA PRIVATE LIMITED |
Director |
11-02-07 |
11-02-07 |
- |
Active |
NO |
|
8 |
U45200MH2007PLC174288 |
BHAKTI
ENTERPRISES LIMITED |
Director |
19-09-07 |
19-09-07 |
- |
Active |
NO |
|
9 |
U45400WB2008PTC123608 |
BHUBANESWAR
PROJECTS PRIVATE LIMITED |
Director |
05-03-08 |
05-03-08 |
- |
Active |
NO |
|
10 |
U45200MH2002PTC137631 |
SHREE
MADHUR REALTORS PRIVATE LIMITED |
Additional
director |
19-08-09 |
19-08-09 |
23-04-11 |
Active |
NO |
|
11 |
U70102MH2009PTC195001 |
KIMAYA
PROPERTY PRIVATE LIMITED |
Director |
30-09-10 |
01-07-10 |
- |
Active |
NO |
|
12 |
U93030MH2011PTC223159 |
AMRITA
IMPEX PRIVATE LIMITED |
Director |
17-10-11 |
17-10-11 |
- |
Active |
NO |
|
13 |
U93030MH2011PTC223440 |
CHAKRA
MERCANTILE PRIVATE LIMITED |
Director |
25-10-11 |
25-10-11 |
- |
Active |
NO |
|
14 |
U93030MH2011PTC223781 |
PUNYA
EXIM PRIVATE LIMITED |
Director |
11-11-11 |
11-11-11 |
- |
Active |
NO |
|
Name : |
Mr. Ravikant Fatehkrishna Sharma |
|
Designation : |
Director |
|
Address : |
Flat No. H 1, Ratrani CD Good Earth, Dongarwaddo Fatorda Margao –
403602 Goa, India |
|
Date of Birth/Age : |
01.03.1978 |
|
Date of Appointment : |
17.09.2003 |
|
DIN No.: |
02386235 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
1 |
U24239MH1992PLC065031 |
AGIO
PHARMACEUTICALS LIMITED |
Director |
17-09-03 |
17-09-03 |
Active |
NO |
|
2 |
U24230MH1996PTC096954 |
REVIVE
PHARMACEUTICALS PRIVATE LIMITED |
Director |
31-05-04 |
31-05-04 |
Active |
NO |
|
3 |
U24231MH1994PTC079977 |
GENOME
PHARMACEUTICALS AND CHEMICALS PRIVATE LIMITED |
Director |
31-05-04 |
31-05-04 |
Active |
NO |
|
4 |
U24230MH1998PTC117547 |
SHREE
FLEX PRINT PRIVATE LIMITED |
Director |
09-02-09 |
09-02-09 |
Active |
NO |
|
5 |
U70102MH2009PTC195001 |
KIMAYA
PROPERTY PRIVATE LIMITED |
Director |
30-09-10 |
01-07-10 |
Active |
NO |
|
Name : |
Mr. Pankaj Nandkishor Chandak |
|
Designation : |
Director |
|
Address : |
502, A Wing, The Crest, Rahatani Road Pune - 411027, Maharashtra, India |
|
Date of Birth/Age : |
08.10.1980 |
|
Date of Appointment : |
19.04.2010 |
|
DIN No.: |
03015380 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
1 |
U24239MH1992PLC065031 |
AGIO
PHARMACEUTICALS LIMITED |
Director |
30-09-10 |
19-04-10 |
Active |
NO |
|
2 |
U24230MH2004PLC148151 |
VIDA
MEDICAREZ LIMITED |
Director |
30-09-10 |
20-08-10 |
Active |
NO |
|
Name : |
Mr. Gautam Sushil Ruia |
|
Designation : |
Director |
|
Address : |
25, Sati Darshan 95, Amersy Road Malad (West), Mumbai – 400064
Maharashtra, India |
|
Date of Birth/Age : |
11.05.1974 |
|
Date of Appointment : |
01.04.2005 |
|
Date of Cessation : |
07.12.2012 |
|
DIN No.: |
02376362 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Date
of cessation |
Company
Status |
Defaulting
status |
|
1 |
U24239MH1992PLC065031 |
AGIO
PHARMACEUTICALS LIMITED |
Director |
01-04-05 |
01-04-05 |
07-12-11 |
Active |
NO |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 30.09.2011
|
Names of Shareholders |
|
No. of Shares |
|
Madhusudan G. Ruia |
|
1360035 |
|
Sanjy G. Ruia |
|
25 |
|
Sita M. Ruia |
|
1126265 |
|
Sageeta Sanjay Ruia |
|
250000 |
|
Madhusudan G. Ruia (HUF) |
|
527165 |
|
Sanjay G. Ruia (HUF) |
|
102890 |
|
Ritika .M. Ruia |
|
50 |
|
Shree Madhur Realtors, India |
|
1125000 |
|
Emfor International, UAE |
|
516865 |
|
Total |
|
5008295 |
As on 30.09.2011
Equity Share Break up (Percentage of Total Equity)
|
Category |
Percentage |
|
Foreign holdings( Foreign institutional investor(s),
Foreign companie(s) Foreign financial institution(s), Non-resident Indian(s)
or Overseas Corporate bodies or Others |
10.32 |
|
Bodies corporate |
22.46 |
|
Directors or relatives of Directors |
67.22 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Prescription Drugs |
|
|
|
|
Products: |
·
Pharmaceutical Products ·
Chemical Products |
GENERAL INFORMATION
|
No. of Employees : |
Not Available |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Bankers : |
Union Bank of India, Mumbai Samachar Branch, 60/80, Mumbai Samachar
Marg, Fort, Mumbai – 400023, Maharashtra, India |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
- |
|
|
|
|
Auditors : |
|
|
Name : |
Banka and Banka Chartered Accountants |
|
Address : |
B-204, Anupam Apartments, opp. Rationing office S.V Road, Malad (west)
Mumbai – 400064 Maharashtra |
|
PAN.: |
AAAFB1145R |
|
|
|
|
Related Parties : |
·
Shree Print and Pack ·
Lifesource Healthcare ·
Genome Pharmaceuticals and Chemicals Limited ·
Bhakti Enterprises |
CAPITAL STRUCTURE
As on 31.03.2011
Authorised Capital:
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
6000000 |
Equity Shares |
Rs.10/- each |
Rs.60.000 Millions |
|
|
|
|
|
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
5008295 |
Equity Shares |
Rs.10/- each |
Rs. 50.083
millions |
|
|
|
|
|
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
50.083 |
50.083 |
34.914 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
322.531 |
309.061 |
195.357 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
372.614 |
359.144 |
230.271 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
528.195 |
392.246 |
367.324 |
|
|
2] Unsecured Loans |
227.871 |
152.971 |
151.266 |
|
|
TOTAL BORROWING |
756.066 |
545.217 |
518.590 |
|
|
DEFERRED TAX LIABILITIES |
9.665 |
11.167 |
5.772 |
|
|
|
|
|
|
|
|
TOTAL |
1138.345 |
915.528 |
754.633 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
363.567 |
390.544 |
382.620 |
|
|
Capital work-in-progress |
3.103 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.611 |
0.510 |
0.500 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
290.559
|
240.964 |
137.392 |
|
|
Sundry Debtors |
557.027
|
415.301 |
294.290 |
|
|
Cash & Bank Balances |
26.513
|
12.197 |
13.829 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
245.624
|
155.320 |
112.994 |
|
Total
Current Assets |
1119.723
|
823.782 |
558.505 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
261.305
|
219.409 |
135.554 |
|
|
Other Current Liabilities |
79.198
|
75.884 |
47.570 |
|
|
Provisions |
8.355
|
4.309 |
4.114 |
|
Total
Current Liabilities |
348.858
|
299.602 |
187.238 |
|
|
Net Current Assets |
770.865
|
524.180 |
371.267 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.199 |
0.294 |
0.245 |
|
|
|
|
|
|
|
|
TOTAL |
1138.345 |
915.528 |
754.633 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
1377.975 |
981.413 |
820.242 |
|
|
|
Other Income |
20.863 |
3.446 |
2.050 |
|
|
|
TOTAL (A) |
1398.838 |
984.859 |
822.292 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Consumption materials changes inventories |
884.086 |
527.178 |
|
|
|
|
Manufacturing service costs |
107.950 |
67.841 |
|
|
|
|
Contract cost |
15.539 |
8.127 |
|
|
|
|
Employee related expenses |
147.557 |
124.677 |
|
|
|
|
Administrative selling other expenses |
87.951 |
110.065 |
|
|
|
|
TOTAL (B) |
1243.083 |
837.888 |
727.918 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
155.755 |
146.971 |
94.374 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
78.914 |
73.662 |
53.884 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
76.841 |
73.309 |
40.490 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
54.822 |
53.050 |
22.003 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
22.019 |
20.259 |
18.487 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
7.965 |
7.486 |
8.060 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
14.054 |
12.773 |
10.427 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
173.762 |
161.575 |
151.673 |
|
|
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
0.584 |
0.586 |
0.525 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
187.232 |
173.762 |
161.575 |
|
|
|
|
|
|
|
|
|
|
TOTAL EARNINGS |
528.357 |
432.935 |
NA |
|
|
|
|
|
|
|
|
|
|
TOTAL IMPORTS |
43.096 |
25.983 |
NA |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
3.14 |
2.39 |
14.93 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
PAT / Total Income |
(%) |
1.00
|
1.30 |
1.27 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
1.60
|
2.06 |
2.25 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
1.48
|
1.67 |
1.96 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.06
|
0.06 |
0.08 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
2.97
|
3.81 |
3.07 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
3.21
|
2.75 |
2.98 |
LOCAL AGENCY FURTHER INFORMATION
Corporate
Overview:
Subject was instituted in 1991 to augment a focused approach towards
global pharmaceutical brand marketing. Today, like the prism they have spread
their aura of being a professionally managed and a committed organization over
several countries.
Careful planning and sound understanding of various countries and their
medical needs, has enabled us to enjoy the trust and support of the medical
fraternities in these countries in the areas of Ethical medicine, OTC medicine,
Herbal formulations and Veterinary formulations. Their pharmaceutical and
veterinary product range includes a combination of over 365 formulations in
over 20 therapeutic segments. Hence they are known as a progressive total
solutions provider with a vision that is global and an expertise which is local
to various markets.
Understanding the various complexities of marketing and compliance of
various international regulatory formalities has facilitated their entry and
helped us establish a strong base in the CIS - spanning over 12 countries and 300
registered products. Along with a vast
operation in CIS countries, they also operate in other parts of the world; such
as Europe, Asia and Africa.
Subject has made inroads into the domestic market of the subcontinent of
India. Presently spanning across India with a field strength of 500 plus, they
have a well-knit distribution channel, penetrating the very interiors of the
country ensuring the availability of quality medicines for every individual,
accessible not only at affordable prices, but also well within reach.
Acknowledging the importance of targeted, customer focused marketing;
Subject has its sales divisions focused around the specialty customer. Their
sales force constantly endeavors to promote their world-class products
Changing pharmaceutical scenarios have encouraged us to initiate
projects into various areas like Bulk Drugs, Nutraceuticals and Consumer
Products. When appropriate, they actively seek opportunities to extend the life
of these products through innovative line extensions.
Form 8:
|
Corporate identity number of the company |
U24239MH1992PLC065031 |
|
Name of the company |
AGIO PHARMACEUTICALS LIMITED |
|
Address of the registered office or of the principal place of business in India of the company |
A-38, Nandjyot Industrial Estate, Kurla Andheri Road, Safed Pool, Mumbai – 400072, Maharashtra, India E-mail: sdarjee@agio-pharma.com
|
|
This form is for |
Creation of charge |
|
Type of charge |
Movable property (not being pledge |
|
Particular of charge holder |
Union Bank of India, Mumbai Samachar Branch, 60/80, Mumbai Samachar
Marg, Fort, Mumbai – 400023, Maharashtra, India E-mail : msmcredit@unionbankofindia.com
|
|
Nature of instrument creating charge |
Term loan agreement (hypothecation of movables) |
|
Date of instrument Creating the charge |
21.12.2011 |
|
Amount secured by the charge |
Rs.14.200 Millions |
|
Brief of the principal terms an conditions and extent and operation of
the charge |
Rate of Interest Interest at base rate + 5.50% per annum with monthly rests. Terms of Repayment Number of installments : 20 Amount of installments : Rs.0.710 Million Tenure : 5 years Margin As per sanction terms. Extent and Operation of the charge To secure the term loan III of Rs.14.200 Millions granted by the bank
to the company. |
|
Short particulars of the property or asset(s) charged (including
complete address and location of the property) |
The borrower hypothecates in favour of the bank - (1) First charge on various equipments / machineries to be purchased
out of term loan III and second charge of COSMOS BANK. (2) All the tangible movable machinery and plant of the borrower
together with spares, tools and accessories and other movables, both present
and future, whether lying loose or in cases which are now lying or stored in
or about or shall be brought into or be stored or be in or upon or about the
borrower's premises and godowns or wherever else the same may be or be held
by any party to the order or disposition of the borrower relating to or
pertaining to the borrower's works at T-81, T-82, MIDC, Bhosari, Pune –
411026, Maharashtra, India |
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals have
been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.51.05 |
|
|
1 |
Rs.81.09 |
|
Euro |
1 |
Rs.67.39 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
6 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
46 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.